Novel Antitumor Agents 3

• 7081 Enzyme hyperactivation to target isocitrate dehydrogenase mutations Erick Gonzalez, Shengqi Hou, Andrew M. Intlekofer
• 7082 · PDF Pseudoginsenoside F11 enhances YBX1-mediated transcriptional repression of PRPS2 to inhibit the stemness and pulmonary metastasis of triple negative breast cancer Kejia Xu, Huimin Liu, Yuting Bai, Haojie Chen, Yi Liu, Yimeng Liu, Xing Wan, Rong Xiang
• 7083 · PDF ABSK211, a highly potent and orally available pan-KRAS inhibitor, demonstrates robust antitumor efficacy in combination with multiple agents Qianqian Chen, Bin Shen, Xiao Chen, Jie Wang, Jie Zhang, Manqi Liu, Hongping Yu, Nannan Zhang
• 7084 beta-Caryophyllene induces apoptosis and inhibits angiogenesisin colon cancer models Loiy Ahmed Hassan, Saad Sabbar, Yasser Tabana
• 7085 · PDF Obscurin-PH as a chemo-sensitizer in triple-negative breast cancer Kelly Griffiths, Matthew Eason, Aikaterini Kontrogianni-Konstantopoulos
• 7086 · PDF Preclinical characterization of a potent and selective Werner helicase (WRN) inhibitor with activity in low-TA repeat microsatellite instability-high (MSI-H) cancers Pablo E. Hollstein, Daniel A. Aiello, Anne Y. Saiki, Keegan S. Cooke, Petia Mitchell, Xiang Yi, Ishwar N. Kohale, Matthew J. Rardin, John Rodgers, Mauro Poggio, Chun Su, Sigurgeir Ólafsson, Doruk Beyter, Jennifer A. Roth, Nuria A. Tamayo, Kevin L. Greenman, Andrew J. Holland, Paul E. Hughes
• 7087 · PDF Optimizing the linker of venetoclax-artemisinin conjugates to improve water solubility and antileukemia effects Jingyi Zhang, Linghui Hou, Zhenwei Zhang, Samuel Waxman, Linxiang Zhao, Yongkui Jing
• 7088 · PDF NAD(P)H: Quinone oxidoreductase 1 (NQO1): Is it a potential molecular target in colorectal cancer? Chaithanya Ganji, Raasil R. Basha, Karthikeya Ganji, Mehmet Akce, Bassel F. El-Rayes
• 7089 · PDF Diphyllin induces autophagy-mediated ferroptosis in liver cancer Jinfang Zhang, Zhanghao Li, Zheng CHEN, Chao Wang, Aiping Lu*
• 7090 · PDF Preclinical characterization of ABSK211: A highly potent, orally bioavailable and selective pan-KRAS inhibitor with broad and robust activity in KRAS-driven tumors Yongxian Zhang, Fei Yang, Zhigang Feng, Meimei Sun, Xinyan Huang, Haibing Deng, Hongping Yu, Haiyan Ying
• 7091 · PDF DWP216, a TEAD1/2 inhibitor, enhances efficacy of diverse KRAS inhibitors by reversing resistance mechanisms in RAS-dependent cancers Bora Yoo, Ye Gi Han, Hye-Been Yoo, Ahreum Kwon, Jiyoon Seok, Youngwoo Choi, Ji-Duck Kim, Hyounmie Doh
• 7092 · PDF Highly potent and mutant-selective p53 Y220C reactivators with best-in-class potential Chiou-Hong Lin, Benjamin C. Milgram, Brendon Ladd, Weixue Wang, John P. Vu, Jun Jacob Hu, Yemin Lan, Keyur Gada, Heidi Koldsoe, Stephanie M. Reeve, Robert Hicklin, Mint Sirisawad, Brendan J. Hilbert, Jack A. Henderson, Simon A. Roberts, Gregory Kryukov, Hsu-Ping Kuo, Natasja Brooijmans, Angel Guzman-Perez, Darrin D. Stuart, Erica L. Jackson
• 7093 · PDF Potential use of MYCN and AURKA dual inhibitors for the treatment of pediatric cancers Nur Awaliyah Mentari Sukma, Wan-Ping Wang, Cheng-Ping Jheng, Chung-Chi Lee, Teng-Kuang Yeh, Jyh-Haur Chern, Ya-Hui Chi
• 7094 · PDF Discovery of QLS1303, a potent and selective KIF18A inhibitor with robust anti-tumor activity in CIN+ preclinical cancer models Fei Chen, Wei Wei, Xiaobing Lv, Xiaoping Zheng, Chen Yang, Lili Fan, Fang Zhang, Junguo Hao, Xinrui Shao, Yan Wu, Ling Li, Ping Chen, Dong Yang, Hua Dong, Guqing Shi, Dongdong Wu, Yanling Xu, Weimei Sun, Liang Xie, Wenyuan Qian, Daqing Sun, Weikang Tao
• 7095 · PDF QLS1403, a novel and potent PARG inhibitor with robust anti-tumor efficacy in homologous recombination deficient cancer models Tingting Xia, Wei Wei, Xiaobing Lv, Jianfei Wang, Shengnan Zhang Zhang, Jun Chen, Xianyun Huang, Guozhi Liang, Lan Zhang, Ling Li, Ping Chen, Dong Yang, Fangfang Chen, Guqin Shi, Jiahua Chu, Dongdong Wu, Weimei Sun, Liang Xie, Wenyuan Qian, Daqing Sun, Weikang Tao
• 7096 · PDF Design and development of a biparatopic antibody-drug conjugate against CDH17 Jinxiu Hou, Lisha Dong, Tingting Gu, Jiyuan Tian, Dandan Liu, Yongxin Shang, Rongmei Yan, Lifeng Pan, Liang Tian, Jian Peng, Zhenping Zhu
• 7097 · PDF Non-clinical characterization of GSK5764227, a novel B7-H3-directed antibody-drug conjugate (ADC) Jeremy Waight, Yuanfeng Zhou, Danni Sun, Lu Zhang, Michael Adam, Dawson Knoblock, Wenjin Zhou, Pengchao Qiu, Jifa Fan, Hannah Chenoweth, Johannes Breuning, Huifeng Niu, Srujana Neelam, Juan Liu, Shannon McKearnan, Natacha Steinckwich-Besancon, Takahiro Sato, Derek Poore, Alexander Cocks, Prajna Behera, Chris Hopson, Kenneth W. Hance, Klaas Bakker
• 7099 · PDF Novel Ect2-Rac inhibitor CPV-337 in breast and pancreatic cancer Jessica Colon Gonzalez, Nilmary Grafals-Ruiz, Anamaris Torres-Sanchez, Cornelis Vlaar, Suranganie Dharmawardhane
• 7100 · PDF VS-7375: An oral, selective KRAS G12D dual ON/OFF inhibitor with potent anti-tumor activity as a single agent and in combination with other agents Silvia Coma, Ian Smith, Cristina Caffarra Malvezzi, Clint A. Stalnecker, Emilia Berardelli, Enrico Patrucco, Fusheng Zhou, Channing Der, Chiara Ambrogio, David G. DeNardo, Jonathan A. Pachter
• 7101 · PDF Discovery of first-in-class YTHDC1 small molecule inhibitors for the treatment of MYC-driven cancers Richard C. Centore, Mark Charles, Mansi Arora, Marius Rebmann, Michael J. Rawling, Jerome Cattin, Xuejing Yang, Emily Batchelor, Matthew Watson, Nagakumar Bharatham, Alexander Howarth, Seema Qamar, Laura Andraghetti, Andrew Seeber, Michael G. Kharas, Sam Cohen, Martin Kulander, Tuomas Knowles, Shilpi Arora
• 7102 · PDF Overcoming cytidine deaminase (CDA) mediated resistance via EO-4426 dual DNA-replication targeting: Implications for CDA-high solid tumors and mesenchymal GBM Jeffrey Bacha, Denni M. Brown, Richard Daniels, Sarath Kanekal, John Langlands
• 7103 · PDF Evaluation of anti-parasitic agents as potential therapeutics in ovarian cancer Aneth Ochoa Negrete, Tiffany Duque, Adithi Kankanala, Gisel Gutierrez, Riyaz Basha
• 7104 · PDF BBO-11818: An orally bioavailable, highly potent and selective non-covalent pan-KRAS(ON) and (OFF) inhibitor with robust anti-tumor activity in KRAS-mutant preclinical models Carlos E. Stahlhut Espinosa, Anna E. Maciag, Kyle A. Sullivan, Kanchan Singh, Nadege Gitego, Zuhui Zhang, Albert H. Chan, Alok K. Sharma, Patrick Alexander, Jin Shu, Yue Yang, Megan Rigby, Roger Ma, Molly Grandcolas, Saman Setoodeh, Brian P. Smith, Jun Pei, Dana Rabara, Erik K. Larsen, David Turner, Cathy Zhang, Cindy Feng, Siyu Feng, James P. Stice, Rui Xu, Ken Lin, Andrew G. Stephen, Felice C. Lightstone, Chunmei Ji, Keshi Wang, Dhirendra K. Simanshu, Dwight V. Nissley, Eli Wallace, Bin Wang, Kerstin Sinkevicius, Frank McCormick, Pedro J. Beltran
• 7105 · PDF Therapeutic targeting of ADAR1 p150 splicing activity impairs CD44 + TNBC cell populations in preclinical studies Wenxue Ma, Jessica Pham, Emma Klacking, Kendale Wirtjes, Inge van der Werf, Peggy Wentworth, Sheldon Morris, James La Clair, Michael Burkart, Catriona Jamieson
• 7106 · PDF Q-2361, a treatment for skin cancer prevention in organ transplant recipients Rebecca Pouwer, Kimberley Beaumont, Margaret Veitch, Maria Parra Reyes, Bhanu Chintala, Hui Yi Chew, Peter Soyer, Scott Campbell, James Wells, Andrew Harvey, Terrie-Anne Cock, Brian Dymock
• 7107 · PDF Dual FLT3/BRAF inhibitor PHI3 overcomes RAS-driven resistance in FLT3-mutant AML Shikhar Sharma, Anna Skwarska, Evangelia Matenoglou, Sovira Chaudhry, Selvam Murugan, Catherine Smith, Pamela Sung, Eunice Wang, Donald Small, Evripidis Gavathiotis, Marina Konopleva
• 7108 · PDF Polyamine depletion via ivospemin and doxorubicin combination treatment leads to alterations in the ovarian tumor immune microenvironment Cassandra E. Holbert, Ashley C. Nwafor, Lauren J. Imasa, Robert A. Casero, Tracy Murray Stewart

在完整检索应用中浏览本分会场 →